SCHEMBL5879128

SCHEMBL5879128

COc1cccc2c(C3=CC(=O)NC3=O)c[nH]c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
DYRK1A Q13627 2/20 0.46
GSK3B P49841 2/20 0.46
NFATC1 O95644 1/20 0.46
HTR2A P28223 1/20 0.44
NR3C1 P04150 2/20 0.43
PGR P06401 2/20 0.43
NR3C2 P08235 2/20 0.43
AR P10275 2/20 0.43
HTR6 P50406 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
CNR2 P34972 1/20 0.40
NQO2 P16083 1/20 0.40
KDR P35968 2/20 0.39
PLK4 O00444 1/20 0.39
AURKA O14965 1/20 0.39
NUAK1 O60285 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879189 0.82 AR (0.46) KDM4EALDH1A1HPGDHTR2AAR
SCHEMBL11323197 0.81 PRMT1 (0.44) KDM4EALDH1A1HPGDNQO2CDK2
SCHEMBL5879217 0.79 CLK1 (0.43) DYRK1AGSK3BARABL1CDK4
SCHEMBL5879156 0.79 AR (0.45) DYRK1AHTR2AARABL1CDK4
SCHEMBL5879149 0.78 HTR2A (0.47) GSK3BHTR2AHTR6MTNR1AMTNR1B
SCHEMBL9085502 0.76 PRKCB (0.67) GSK3BKDRPLK4AURKANUAK1
SCHEMBL211026 0.76 L3MBTL1 (0.51) KDM4EALDH1A1HPGDGSK3BMEN1
Ammonia Solution, Strong SCHEMBL27959164 0.75 L3MBTL1 (0.54) KDM4EALDH1A1HPGDGSK3BMEN1
SCHEMBL5879251 0.75 CDK4 (0.45) KDM4EALDH1A1HPGDGSK3BMTNR1A
SCHEMBL28079947 0.75 CA1 (0.44) KDM4EALDH1A1HPGDGSK3BEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 KDM4E 3154/4885ALDH1A1 286/4885HPGD 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.